AV GBM immunotherapy promising?…
AV GBM immunotherapy promising?
AIVITA Biomedical Announces New Positive Phase 2 Glioblastoma Data at SITC Annual Meeting Podium Presentation
IRVINE, Calif. – November 12, 2019 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that data from its ongoing Phase 2 clinical trial in GBM was presented at the Society for Immunotherapy of Cancer Annual Meeting by Principal Investigator Dr. Daniela Bota. The oral presentation was titled “Phase